These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

910 related articles for article (PubMed ID: 33073374)

  • 21. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
    El-Adl K; El-Helby AA; Sakr H; Elwan A
    Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors: Design, synthesis, and anti-proliferative evaluation.
    Eissa IH; El-Helby AA; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; El-Adl K
    Bioorg Chem; 2020 Dec; 105():104380. PubMed ID: 33128967
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
    Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
    Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New bis([1,2,4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and anticancer evaluation.
    Alanazi MM; Mahdy HA; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Dahab MA; Eissa IH
    Bioorg Chem; 2021 Jul; 112():104949. PubMed ID: 34023640
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
    Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, anticancer, and docking of some S- and/or N-heterocyclic derivatives as VEGFR-2 inhibitors.
    El-Adl K; Abdel-Rahman AA; Omar AM; Alswah M; Saleh NM
    Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100237. PubMed ID: 34862655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study.
    El Hamaky NFM; Hamdi A; Bayoumi WA; Elgazar AA; Nasr MNA
    Bioorg Chem; 2024 Jul; 148():107437. PubMed ID: 38749114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents.
    Ahmed EY; Abdel Latif NA; El-Mansy MF; Elserwy WS; Abdelhafez OM
    Bioorg Med Chem; 2020 Mar; 28(5):115328. PubMed ID: 31992477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, and anti-proliferative evaluation of new quinazolin-4(3H)-ones as potential VEGFR-2 inhibitors.
    El-Adl K; El-Helby AA; Ayyad RR; Mahdy HA; Khalifa MM; Elnagar HA; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Eissa IH
    Bioorg Med Chem; 2021 Jan; 29():115872. PubMed ID: 33214036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
    Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
    Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of new 1,6-dihydropyrimidin-2-thio derivatives targeting VEGFR-2: Molecular docking and antiproliferative evaluation.
    Marzouk AA; Abdel-Aziz SA; Abdelrahman KS; Wanas AS; Gouda AM; Youssif BGM; Abdel-Aziz M
    Bioorg Chem; 2020 Sep; 102():104090. PubMed ID: 32683176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
    Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
    Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
    Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
    Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, in silico and antiproliferative evaluation of novel pyrazole derivatives as VEGFR-2 inhibitors.
    Ravula P; Vamaraju HB; Paturi M; Sharath Chandra JNGN
    Arch Pharm (Weinheim); 2018 Jan; 351(1):. PubMed ID: 29205467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phthalazine-based VEGFR-2 inhibitors: Rationale, design, synthesis, in silico, ADMET profile, docking, and anticancer evaluations.
    Khedr F; Ibrahim MK; Eissa IH; Abulkhair HS; El-Adl K
    Arch Pharm (Weinheim); 2021 Nov; 354(11):e2100201. PubMed ID: 34411344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
    El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
    Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
    Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
    Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel NO-TZDs and trimethoxychalcone-based DHPMs: design, synthesis, and biological evaluation as potential VEGFR-2 inhibitors.
    Mahnashi MH; Nahari M; Almasoudi H; Alhasaniah A; Elgazwi S; Abou-Salim MA
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2358934. PubMed ID: 38904116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-
    Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Elwan A; Elkady H
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1093-1114. PubMed ID: 34056992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.